Use

Guardant360 Tissue is a comprehensive multiomic tissue molecular profiling test for patients with advanced solid tumors, incorporating genomic, transcriptomic, and epigenomic analysis (including DNA, RNA, tumor methylome, and AI-powered PD‑L1 assessment) to provide a more complete view of cancer and facilitate personalized treatment selection. It requires 92% less tissue surface area and 40% fewer slides than industry standard, increasing applicability for more patients. Results are available in less than two weeks, and the test is covered by Medicare for eligible patients. (Source: Guardant Health press release, April 28, 2025; Guardant portfolio page) cite cite